|
關(guān)于回復(fù)審稿意見，之前我們推送過一些內(nèi)容。目前大家可能更需要真實案例來進(jìn)一步學(xué)習(xí)和鞏固。因此，我們整理了Nature Conmmunication近期（3月11日）2篇論文的部分審稿意見，供大家參考（全文獲取方式見文末）。 
鏈接：https://www./articles/s41467-021-21841-w Review#2: 作者應(yīng)當(dāng)簡短的討論一下最近……等人的工作。 感謝這位審稿人的建議。最近的一項研究表明雷帕霉素治療可以降低……而在我們的研究中，這種治療并沒有明顯影響……我們注意到該研究里的雷帕霉素治療遠(yuǎn)高于我們研究中使用的濃度，在這種高濃度下，該治療可以……從而抑制……（尋找與前人文獻(xiàn)結(jié)果不一致的原因）We thank this reviewer for the suggestin. A recent study showed rapamycin treatment can decrease……, whereas in our study rapamycin treatment did not obviously affect …… We noticed that the rapamycin concentration used in this study (25μM) was much higher than that used in our study .It is possible that rapamycin at such high concentrations can……and thereby suppress …….另一項研究表明，mTORC1調(diào)節(jié)……，然而該研究表明，雷帕霉素治療甚至增加了……需要進(jìn)一步的研究來澄清這些問題。Another previous study indicated that mTORC1 regulates ……. However, this study showedthat rapamycin treatment even increased……. Further studies are needed to clarify these questions.我們已經(jīng)在手稿里討論并引用了相關(guān)的文獻(xiàn)。We now discussed and cited these relevant publications. Reviewer #1：新的結(jié)果發(fā)現(xiàn)……這與手稿的主要結(jié)論矛盾。這是作者需要徹底說明的。 感謝審稿人提出有洞察力的問題。我們承認(rèn)，我們目前還不了解機(jī)制層面上的這種調(diào)節(jié)選擇性，但是我們想指出，在概念層面上，這在生物系統(tǒng)中是相當(dāng)普遍的。We thank the reviewer for asking this insightful question.We acknowledge that we currently do not understand this regulation selectivity on the mechanistic level, but want to point out that, at the conceptual level, this is quite common in biological systems.如圖1所示，mTORC1接受來自不同刺激的信號輸入……一旦被激活就能促進(jìn)……。去除……都可以有效地抑制mTORC1的活性；然而，……不會導(dǎo)致……的抑制。例如，已有研究表明，……As illustrated in rebuttal letter Fig. 1, mTORC1 receives signaling inputs from …… Once activated, mTORC1 functions to promote……. Removal of ……can all potently suppress mTORC1 activity ……; however, ……would not cause the suppression of ……. For example, it has been shown that …… 有幾種機(jī)制可以解釋這種情況：（1）……（2）……（3）……Several mechanisms can account for such a selectivity in signaling regulation……由于我們目前的研究不是為了了解……對……的不同影響，我們希望這位審稿人能同意，解決這些問題超出了本研究的范圍。我們已經(jīng)將這些討論納入了我們的手稿，并希望這將促進(jìn)未來對這一有趣問題的研究。（態(tài)度委婉地表明審稿人的問題超出了研究范圍）As our current study is not set out to understand the differential effects of…… on ……, we hope this reviewer will agree that addressing these questions is beyond the scope of this study. We have incorporated these discussions into our manuscript, and hope that this will stimulate future studies on this interesting question.Reviewer #4：該論文詳細(xì)介紹了實驗方法的許多方面……令人遺憾的是，還有更廣泛的關(guān)于實驗設(shè)計和結(jié)果展示的解釋是缺乏的。 我們同意這位審稿人的觀點(diǎn)，即方法部分應(yīng)該包括詳細(xì)的實驗條件，這樣其他研究人員就可以在未來復(fù)制我們的發(fā)現(xiàn)。根據(jù)這位審稿人的友好建議，我們提供了實驗設(shè)計的流程圖，希望這可以幫助讀者廣泛地理解我們的實驗方法。之后的回復(fù)也會有更多細(xì)節(jié)。（用圖表豐富實驗細(xì)節(jié)，便于其他研究者進(jìn)行重復(fù)實驗）We agree with this reviewer that the Methods section should include detailed experimental conditions so that other researchers can replicate our findings in the future. Following the kind suggestion of this reviewer, we now provide a flowchart of our proteomic experimental design,which we hope can help the readers to understand broadly our experimental approach.Our response below will provide additional clarifications and answers to this reviewer’s questions.
鏈接：https://www./articles/s41467-021-21300-6#Sec20
Reviewer #1 ……通路分析相對缺乏信息……沒有進(jìn)行與……變化等相關(guān)的假設(shè)檢驗……不清楚這些描述性質(zhì)的數(shù)據(jù)如何拓展我們現(xiàn)有的知識？ 我們感謝審稿人的建議。我們對圖4C進(jìn)行了更新，并對段落……進(jìn)行了大量編輯，以澄清我們不打算提供藥物預(yù)測分析……We thank the Reviewer for the suggestions. We have updated Fig.4C and introduced substantial edits to the paragraph……to clarify that we do not intend to provide a drug prediction analysis……關(guān)于路徑假設(shè)檢驗，我們更新了先前版本的手稿中包含的分析。我們進(jìn)行了差異表達(dá)分析，隨后對……進(jìn)行了GSEA分析，以確定……之間的一致性模式。路徑選擇基于……（根據(jù)意見重新分析數(shù)據(jù)）In regard to pathway hypothesis testing, we have updated the analysis included in the previous version of the manuscript. We have performed differential expression analysis followed by GSEA for ……to identify concordance patterns among ……. The selected pathways were chosen based on ……正如審稿人所說，已有公開的……，我們在修訂后的手稿中加入了對新研究的進(jìn)一步參考。然而，這些大多數(shù)來自……，由于患者接受……，獲得了耐藥性特征。相比之下，早期……As the Reviewer indicated, there are publicly available cohorts of …… and we have included further references to new studies in the revised manuscript.However, the majority of these cohorts are from ……, which have already acquired resistance traits due to ……. In contrast, there is limited availability of early stage ……我們建立的PNPCa模型提供了……，它保留了……因此，它可以作為與晚期PCa疾病模型比較的參考點(diǎn)(早期)。我們現(xiàn)在已經(jīng)在手稿中加入了一項新的分析，比較了……的基因表達(dá)譜。（強(qiáng)調(diào)研究價值，補(bǔ)充新分析后的圖片）The PNPCa model that we have established represents ……, which retains ……. Thus it may serve as a reference point (early stage) for comparison with models of advanced PCa disease. We have now included a new analysis in the revised manuscript, comparing the gene expression profiles of…… 本期回復(fù)意見原文可在公眾號后臺回復(fù)“317意見”獲取哦~大家還想看什么領(lǐng)域的審稿意見回復(fù)案例呀？在下方投個票吧 ！
|
